Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1493-e1499. doi: 10.1016/j.cgh.2021.12.007. Epub 2021 Dec 9.

Abstract

Immunization against the spike protein of SARS-CoV-2 reduces transmission1,2 and severe outcomes. However, little is known regarding the impact of immune-mediated diseases and immunosuppressive medications on the efficacy of vaccination. Vaccination immunity is transient, with breakthrough cases increasing at longer time intervals since the last dose.3,4 Although there are data on SARS-CoV-2 vaccine on early seroconversion in patients with inflammatory bowel disease (IBD),5 no data in the same cohort exist describing the durability of these antibodies over time. We sought to investigate the impact of IBD and its therapies on postvaccination antibody response and kinetics of immunogenicity decline, because these findings may better inform clinical guidelines and recommendations on precautions and booster vaccination.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / therapeutic use
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / prevention & control
  • Chronic Disease
  • Humans
  • Immunity, Humoral / drug effects
  • Inflammatory Bowel Diseases* / drug therapy
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines

Supplementary concepts

  • Inflammatory Bowel Disease 5